arrow
A

Aysegül Ilhan-Mutlu

department of medicine i - division of oncology
H指数:25
被引数:2,486

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cause-Specific Mortality in Gastroesophageal Cancer: A 30-Year Real-World Analysis from the Vienna Gastroesophageal Cancer Database

胃癌和食管癌的病因特异性死亡率:来自维也纳消化道肿瘤数据库的30年真实世界分析

2026-08-150
OAAI
Therapeutic management of resectable mismatch-repair deficient/microsatellite instability-high gastroesophageal adenocarcinoma: a real-world analysis from Austria

可切除错配修复缺陷/微卫星高度不稳定胃癌的疗法管理:来自奥地利的真实世界分析

2026-07-230
OA
Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort

先前或并发恶性肿瘤与胃癌患者总生存期之间缺乏关联:来自一项大型欧洲单中心队列的证据

2025-08-290
OAAI
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases

曲妥珠单抗-deruxtecan治疗活动性脑转移的HER2-positive乳腺癌患者的II期TUXEDO-1试验的最终结果分析

2024-07-048
OAAI
FINAL OUTCOME ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-POSITIVE BREAST CANCER PATIENTS WITH ACTIVE BRAIN METASTASES
2024-05-020
PRE
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study
2023-03-072
PRE
NEURON-SPECIFIC ENOLASE (NSE) AND S100 SERUM LEVELS IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HER2-POSITIVE BREAST CANCER TREATED WITH TRASTUZUMAB-DERUXTECAN (T-DXD): A BIOMARKER ANALYSIS FROM THE TUXEDO-1 TRIAL
2022-09-050
OA
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
2022-08-08223
OAAI
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment

程序性细胞死亡蛋白1 (PD-1) 和程序性细胞死亡蛋白1配体 (PD-L1) 在胃食管交界处腺癌中的表达在新辅助治疗后显着变化

EJSO
IF2.9
2022-02-016
PRE
Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
2021-09-0118
OAAI
Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs
2020-12-2223
OAAI
Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
2020-09-0333
OAAI